In patients with cystic fibrosis (CF), treatment of new Pseudomonas aeruginosa (Pa) infection postpones the occurrence of chronic infection, but the best eradication regimen is unknown . Aim of the study: Compare 2 Pa eradication regimens in children with new Pa infection. Methods: Children with CF (0-18 years) and a new isolation of Pa from sputum, cough swab or BAL were randomized to treatment with tobramycin inhalation solution for 28 days (TIS) or inhaled sodiumcolistimethate (2 × 2 mill U/day) plus oral ciprofloxacin (30 mg/kg/day) for 3 months (CC). Airway cultures were taken for 6 consecutive months, then every 3 months. The primary outcome was Pa eradication at the end of treatment. Secondary outcome parameters were: time to Pa relapse from end of treatment, total and Pa specific IgG, FEV 1 , BMI and Pa status at 2 year follow-up. Results: 58 patients with new Pa isolation were randomized. Their median age was 9 years (IQR 4.7-13.1) and their median FEV 1 98% predicted (IQR 87-107). Eighteen treatments concerned the first Pa isolation 'ever' (TIS: 8; CC: 10). For the remaining, median time since previous Pa was 19 months (IQR 9-41). Eradication at end of treatment was similar for both treatments: 26/29 CC and 23/29 in TOBI treated patients (p = 0.47). Median time to recurrence of Pa was 9 months (95% CI 0.0-19.0) for CC and 5 months (95% CI 1.7-8.3) for TIS (p = 0.608). After 1 year, the 2 groups did not differ in change in total and Pa specific IgG, FEV 1 and BMI. After 2 years, 10% of patients had chronic Pa infection. Conclusion: In children with CF and new Pa infection, inhalation of TIS (28 days) or CC (3 months) resulted in similar eradication success at the end of treatment (80 and 90% respectively) and similar clinical evolution during the first 2 years of follow-up.
Introduction
In children with cystic fibrosis (CF), Pseudomonas aeruginosa (Pa) lung infection is associated with increased morbidity and mortality [1] [2] [3] . Especially chronic Pa lung infection and/or conversion to a mucoid Pa phenotype are associated with more rapid decline in lung function [3] .
Intermittent Pa colonization nearly always precedes chronic infection, and this window of opportunity can be utilized to eradicate Pa from the respiratory tract. Because the combination of inhaled colistin plus oral ciprofloxacin was the first treatment regimen proven to postpone chronic Pa infection [4, 5] , this treatment is still commonly used across Europe [6] . In recent years, other antibiotic eradication therapies for new or early Pa infection have been evaluated [7, 8] , and diverse treatments are currently used. In Europe, the most common approach for eradicating Pa infection continues to be nebulized colistin in conjunction with oral ciprofloxacin (43%), closely followed by nebulized tobramycin (41%) [6] .
Using these regimens, the initial Pa eradication efficacy varies from 25 to 100% with a median time to relapse of Pa infection from 8 to 18 months [4, 5, 7, [9] [10] [11] [12] [13] [14] [15] . Treatment with oral ciprofloxacin and inhaled sodiumcolistimethate (both for a period of 3 months) protected 80% of children from chronic Pa infection up to age 15 years [5] . Using this same eradication protocol, variable eradication success and times to relapse were reported in other retrospective or non-randomized studies [16] . Inhaled tobramycin monotherapy has also proven effective in eradicating early Pa infection [7] . In recent studies the high dose formulation of tobramycin for inhalation (TIS) is used. TIS administered twice daily for 28 days was superior to placebo [15] , but in the ELITE trial, TIS treatment for 56 days was not superior to TIS treatment for 28 days [7] . In the EPIC trial, TIS was used as monotherapy or combined with oral ciprofloxacin either as a cycled therapy or whenever Pa was cultured from the respiratory secretions [8] . The addition of ciprofloxacin and prophylactic cycles of treatment was not more effective than TIS monotherapy or TIS at time of new Pa infection only.
Since comparative data for TIS versus inhaled colistin plus oral ciprofloxacin (CC) are not available, we conducted a monocentric prospective randomized open label trial comparing CC with inhaled TIS monotherapy for the eradication of new Pa infection in a real life clinical setting.
Patients and methods

Study design
This is a single center open label prospective randomized trial. During the time of the study (August 2004-August 2010) all pediatric patients with first Pa infection ever or new Pa infection after at a Pa free period of at least 6 months were assessed for participation.
Inclusion criteria were: 1. diagnosis of CF (clinical signs consistent with CF and a sweat chloride N 60 mEq/l by quantitative pilocarpine iontophoresis and/or two CF causing mutations identified), 2. age 0 to 18 years at time of inclusion, 3. First or new Pa infection was defined as the first Pa isolation ever or isolation of Pa from the airway (sputum, throat swab or BAL) after a Pa free interval of at least 6 months and documented with at least 3 negative cultures.
Exclusion criteria were: 1. chronic Pa infection according to the Leeds criteria [18] , 2. pulmonary exacerbation needing intravenous antibiotic (IV AB) treatment at the time of Pa isolate, 3. Pa isolation at the time of CF diagnosis, 4. patient already on antipseudomonal antibiotics and 5. interval between positive culture and start of treatment N 4 weeks.
Patients were randomized 1:1 to oral ciprofloxacin (30 mg/ kg/day) combined with inhaled colistin (Colistineb® Forest Laboratories, Kent UK) (2 mill units BID) (CC) for 3 months or monotherapy with tobramycin inhalation solution (TIS) (TOBI ® Novartis Pharma AG, Basel, Switzerland) 300 mg bid for 28 days. Block randomization was used per 10 patients. Study duration was 1 year with follow up for Pa status until 2 years after inclusion. Approval of the local ethical committee was obtained and parental written informed consents were used.
The primary outcome was Pa eradication at the end of the treatment i.e. culture taken at 28 days (TIS) or 3 months (CC). Secondary outcome parameters were time to new Pa positive culture (=relapse; calculated from end of treatment) and Pa eradication 6 months after study entry. Additionally, 1 year after study entry, FEV 1 % change from baseline, IgG (Nephelometry, Beckman-Immage 800) z score change from baseline [19] and BMI z score change from baseline were calculated. Pa antibodies (ELISA St Ag 1-17) [19] were determined at 1 year and Pa status was assessed 1 and 2 years after study entry and reported as 'Free of Pa', 'Intermittent Pa infection' or 'Chronic Pa infection' according to the Leeds criteria [18] .
Patient management
Patients were examined in the outpatient clinic every 3 months and spirometry was performed in patients N5 years of age. FVC and FEV 1 were expressed as % predicted according to Wang [20] .
If the airway culture was still Pa positive at the end of the treatment, patients were changed to the other treatment arm ('rescue treatment'). In case of Pa relapse within 6 months of study entry, patients were started on CC for 3 months or received IV antipseudomonal antibiotics if clinically indicated. If during the first 6 months, administration of additional antibiotics (oral, inhaled or IV) was clinically indicated (without Pa relapse) this was registered as 'additional symptomatic treatment'. In case of medication intolerance, the patient was changed to the other treatment arm (but analyzed in the original randomization arm).
Airway cultures
After study entry, airway cultures were performed monthly for 6 months, then every 3 months. Sputa, cough swabs and bronchus aspirates were inoculated on Columbia Agar Base (CMO331; Oxoid, Basingstoke, UK) with 5% defibrinated horse blood, MacConkey agar (CM0007; Oxoid), Mannitol Salt agar (CM0085; Oxoid) and Burkholderia cepacia Medium (MAST DM253 D + SV22). MacConkey agar and Mannitol Salt agar were aerobically incubated at 37°C for 48 h, Columbia Blood agar in 5% CO 2 at 37°C for 48 h and Burkholderia cepacia medium aerobically at 37°C for 7 days. Different Pa phenotypes in each patient were identified using a combination of conventional identification methods (growth at 42°C, positive oxidase, nitrate reduction and arginine dehydrolase), as well as the Vitek 2 system (BioMérieux, Marcy l'Etoile, France), cellular fatty acid analysis by gas chromatography and since 2010 with mass spectrometry analysis.
The susceptibility of Pa isolates was determined by disc diffusion (RoscoNeosensitabs) for mucoid strains and with Vitek 2 system for other phenotypes.
Statistical analysis
Sample size calculations were based on previous data for Pa eradication for CC (80%) [5] and TIS (between 74% and 90%) [11] , a delta (defining equivalence range of non-inferiority margin i.e. clinical acceptable difference between the two arms) of 0.15, power of 80% and alpha of 0.05. For a hypothetical initial eradication rate of 83% (CC) and 89% (TIS), 34 patients were needed in each arm (The POWER procedure, Pearson Chi-square test for two proportions).
Statistical analysis was performed with PASW statistics 18 (SPSS Inc). The proportion of patients with successful eradication, Pa status and Pa Ab above cut-off were compared for the 2 treatment groups using Fisher's exact test. Time to recurrence was analyzed by the Kaplan-Meier method (using log-rank test) using t = 0 at the end of treatment in each group.
Changes from baseline for FEV1% pred, IgG z score, BMI z score,, IgG z score and Pa antibodies [19] were compared with the Kruskal-Wallis test.
Results
Baseline demographic and clinical characteristics
Over the 6 year study period, 109 episodes of new Pa infection were documented (i.e. on average 18 Pa isolations/ year met the study definition). Sixty one were randomized and 58 completed the study (for patient disposition see Fig. 1 ). The main reason for exclusion was the need for IV AB treatment. First ever Pa infections were seen in 10 (CC) and 8 (TIS) patients. Pa isolate at study entry had a mucoid phenotype in 2 patients in each arm.
Baseline characteristics were similar between the treatment groups ( Table 1) . The youngest child was 1 year of age; 4 children were younger than 2 years.
During the course of the study the percentage of cultures taken from sputa was 35% in the TIS and 40% in the CC group. In each group one sample was from BAL.
Time since previous Pa was ≤ 12 months in 22.5% of included patients (6 out of 19 CC and 3 out of 21 in TOBI group), excluding patients with their first Pa infection ever (p= 0.277). 
Efficacy
Pa eradication at end of treatment was similar in both groups: 23 out of 29 (79.3%) in the TIS group versus 26 out of 29 (89.7%) in the CC group (relative risk 0.88, 95% CI 0.71-1.11). (Fig. 2) . Three patients failed eradication at the end of therapy in the CC group: 2 were treated with IV antibiotics and 1 was changed to the other treatment arm (i.e. TOBI). Six patients failed eradication at the end of therapy in the TIS group: 2 were treated with IV antibiotics followed by CC; 4 were changed to the other treatment arm (i.e. CC). The outcome of patients with failed eradication is shown in Fig. 2 .
Median time to recurrence of Pa positive cultures calculated at the end of treatment and analyzed by Kaplan Meier survival was 9 months (95% CI 0.0-19.0) for CC and 5 months (95% CI 1.7-8.3) for the TIS group (Log rank p = 0.608) (Fig. 3) . Nineteen (CC) and 13 (TIS) patients were still Pa free 6 months after inclusion into the study (see Fig. 2 ) (p = 0.78).
Pa status at 12 and 24 months
In patients with successful eradication with the study drug, Pa status at 1 year follow-up was Free off/Intermittent/Chronic in respectively 13/13/0 patients in the CC and 13/8/1 (p = 0.461) in the TIS group. Three out of 58 patients had chronic Pa infection after 1 year follow-up. Of the 47 patients with 2 year follow-up, 5 had developed chronic Pa (10%) (Fig. 2) .
Two year follow up data of Pa status were available for 3 of the 4 patients with mucoid Pa at entry into the study: 1 Chronic (TIS), 1 Intermittent (TIS) and 1 Free off (CC).
At time of inclusion into the study, 6 of the 58 patients had detectable anti-pseudomonas antibodies (Pa Ab) level (≥1 and ≤9 AU). One year later, one patient in the CC group developed a level of Pa Ab level N 17 AU consistent with chronic infection [19] .
Additional antibiotic treatment because of symptoms from inclusion until 6 months follow-up
The number of days on additional oral antibiotic treatment (started for symptoms, not because of failed eradication) was similar in the TIS and CC groups. There was also no difference in the number of IV AB courses (14 day combination of tobramycin and either ceftazidim, meropenem or piperacillin-tazobactam) given because of symptoms at time of recurrence of Pa infection (4 CC, 3 TIS) .
Medication intolerance
One patient was intolerant of TOBI® (severe cough) and was changed to CC. 
Lung function, nutritional status, IgG and Pa Ab
Median change from baseline in FEV 1 % after 1 year was − 1% (IQR − 9 to 8%) for the whole group (35 patients were able to perform lung function) and did not differ between the treatment groups. BMI z score and weight z score did not change significantly during the 1 year study. Change in median IgG z score after 1 year did not differ between the treatment groups (median 0, IQR − 0.60 to + 0.44).
Discussion
To eradicate a new Pa infection in children with CF, oral ciprofloxacin plus inhaled sodiumcolimesthate for 3 months was not inferior to 28 days of tobramycin inhalation solution. Immediate eradication was high and comparable for both groups (89.7% and 79.3% respectively). Median time to relapse was similar with both treatment regimens (9 months (95% CI 0.0-19.0) for CC and 5 months (95% CI 1.7-8.3) for the TIS group). Because Pa genotyping was not performed, our data do not allow us to differentiate between true re-infection and recurrence of infection with the same Pa strain.
We acknowledge that there is a profound difference in treatment intensity between both regimens: 28 days of treatment with one antibiotic versus 3 months with two antibiotics. The advantage of TIS is a shorter treatment period with 1 medicine, possibly leading to better treatment adherence and lesser risk of drug toxicity. CC as well as TIS are however well established therapeutic interventions for new Pa infection and therefore it is important to compare them. Since TIS is not licensed for Pa eradication, TIS is not reimbursed in this indication in Belgium. We therefore thought it extra useful to compare both regimens. Combination therapy with oral ciprofloxacin plus an inhaled antibiotic during 3 months is still commonly used in CF centers across Europe [6] . Some centers use a 3 to 4 week treatment course, especially in asymptomatic patients. Using the prolonged treatment does not seem to lead to colistin resistance, and even after use for 15 years only a minimal risk of ciproxin resistance was reported [16] . The adverse event pattern of quinolones is similar in adults and children [21] . Because of animal toxicity data, the concern of damage to the cartilage in growing children remains. However when specifically monitored in children with CF, the safety data were reassuring [21] . Close monitoring is warranted specifically for arthralgia. Also monitoring of drug resistance and emergence of other pathogens is necessary.
There are only 2 head to head comparisons of different eradication regimens [8, 22] . A very recent study [22] compared a 28 day treatment with oral ciprofloxacin and either inhaled colistin or tobramycin. Pa was eradicated by 62.8% in the cipro/ colistin arm and by 65.2% in the cirpo/tobramycin arm B (OR 0.90, 95% CI 0.52 to 1.55, p = 0.81). In the literature, the success of eradication and time to relapse after treatment for new Pa vary widely [4, 5, 7, 9, [11] [12] [13] [14] [15] [16] [17] [23] [24] [25] . Differences in treatment schedules, patient populations (age, first or recurrent Pa infection, time since previous Pa infection), types (BAL, sputum or cough swab) and frequency of airway culture sampling may explain this variation in efficacy. When IV treatment followed by CC was studied, a 100% Pa eradication was documented with a median time to recurrence of Pa of 8 months compared to 90% eradication and a median time to recurrence of Pa of 9 months in the CC group in our study. In a case series only including patients with 'first Pa ever', median time to recurrence after CC was 18 months [12] . The first data using TIS for Pa eradication (28 days versus 56 days) based on follow-up BAL at different time intervals in patients younger than 6 years showed a lower proportion of eradication (74%) [14, 15] compared to the current study. When also taking into account oropharyngeal cultures, eradication success was even lower (around 60%) with only 10 of 21 patients having negative OP cultures within the first 6 months. A very high (90%) and prolonged eradication (only 35% relapse after 1 year) was achieved in the ELITE trial for patients randomized to 56 days as well as to 28 days of TIS [7] . This study included patients with first Pa ever as well as new Pa after 4 negative sputa over 1 to 2 years, with 60% of patients belonging to the first category. In our study, only 1 out of 3 treatments concerned a first Pa infection ever. In the remainder, time since previous Pa ranged from 7 to 37 months (in 25% of patients with previous Pa isolation it was less than 12 months). This most likely explains the lower Pa eradication success and higher relapse in our study compared to the ELITE trial. But our extended inclusion criteria mimic the real life setting, where eradication therapy is still attempted for all recurrences of Pa in airway cultures of patients with CF who are not yet chronically colonized by Pa.
The final goal of early Pa treatment is to postpone chronic infection. In our study, only 10% of patients had chronic Pa infection after a 2 year follow-up based on culture data and only 1 patient showed a Pa antibody titer concordant with chronic infection. Moreover, 1 year after the eradication treatment, the FEV 1 % change from baseline was only −1% (IQR −9 to 8%) and BMI z score remained stable, thereby confirming a stable clinical status. Given the variety of interventions after the 6 month time point, the Pa status at 24 months is likely to be the result of more than the initial eradication therapy. However the current study highlights that, in the majority of patients with new Pa isolation, chronic Pa infection can be postponed for at least 24 months.
This study was underpowered, due to the limited size of our clinic (N= about 150 children) and the rather high percentage of children treated with IV AB at time of new Pa infection. However, the inclusion rate of eligible patients was high and the 2 groups were comparable at baseline. In the ELITE study 45 and 43 patients were randomized but the efficacy population concerned 34 and 31 patients only, which is close to the numbers included and analyzed in our study.
We can conclude that CC and TIS prove effective for immediate eradication of new Pa lung infection, but with high relapse rates within 6 months. The high relapse rate is most likely inherent to the use of the liberal inclusion criteria of being Pa free for at least 6 months, rather than for 1 or 2 years as used in other studies [7, 8, 11] . Also in our cohort however, chronic Pa colonization was postponed in most children with CF. Our study thereby confirms that CC continues to be an effective eradication regimen which is not inferior to 28 days of TIS.
